Anesthetic, analgesic, and muscle relaxant drugs produce varying effects on electroencephalographic (EEG) activity. In the first part of this review article, we described the pro-and anticonvulsant effects of the inhaled anesthetics and the opioid (narcotic) analgesics. Variations in drug dosages, methods of drug administration, and EEG documentation, as well as differences in the patient populations, contribute to the contrasting effects of these drugs on central nervous system (CNS) activity.
In the second part of this pharmacologic review, we describe the reported EEG effects of the sedativehypnotic compounds (including the barbiturates, etomidate, benzodiazepines, ketamine, and propofol), local anesthetics, muscle relaxants, anticholinesterases, and anticholinergics. The evidence for druginduced changes in EEG activity will be critically reviewed with respect to the patient population (i.e., epileptic vs nonepileptic), documentation (i.e., EEG vs clinical signs), and methodology (i.e., surface vs depth electrodes).
Intravenous Anesthetics
Sedu f ive-Hypnat ics Barbiturates . In patients without a history of seizure disorder, low doses of thiopental and methohexital can cause activation of the EEG producing 15-30-Hz waves. With increasing doses of these sedative-hypnotic drugs, slower waveforms of higher amplitude appear that progress to burst suppression at high doses (157) (158) (159) (160) (161) (Figure 3 ). Electroencephalographic or clinical seizure activity has not been reported in nonepileptic patients treated with these ultrashort-acting barbiturates (Table 5) . However, excitatory phenomena such as abnormal muscle movements, hiccoughing, and tremor may occur with both thiopental and methohexital. These excitatory side effects are more common with methohexital (64,162,163). The tendency of methohexital to provoke convulsions during intravenous induction (0.5-1 .O mgikg) in patients with a history of epilepsy is well known (164) (165) (166) (Table 5) . Seizure activity has also been reported after intramuscular (10 mg/kg) or rectal (25 mg/kg) methohexital administration in children with temporal lobe epilepsy (167) . Low-dose (50.5 mgikg) methohexital has proved valuable in the activation of cortical EEG seizure discharges in patients with psychomotor (temporal lobe) epilepsy (11, 12, 168) . This technique has been used during intraoperative electrocorticography to activate epileptic foci during temporal lobectomy (12). Methohexital also adds valuable negative EEG evidence in cases of suspected behavior disorders (11). Only nonspecific EEG effects have been reported after methohexital administration to patients with a history of generalized seizure disorders (11,159).
In three epileptic patients, thiopental activated brief periods (<7 s) of bilateral atypical and polyspike waves during induction, which were not associated with observable seizures (63). The brief periods of spike waves detected in this report were most likely associated with "light" levels of thiopental anesthesia, an accepted method for eliciting convulsive tendencies (25,53,169). Similar intermittent spiking activity also was detected with depth electrodes after low doses of thiopental (<1.5 mg/kg, IV) administered to patients with temporal lobe epilepsy (53). Furthermore, larger doses of thiopental (>5 mg/kg, IV) produced EEG patterns in these epileptics, which closely resembled the changes produced by the drug in normal patients (16,25) (Table 5) . In patients with psychomotor epilepsy in whom methohexital produced EEG and clinical seizure activity, subsequent administration of thiopental did not (12).
In humans, thiopental has well-known anticonvulsant properties (Table 6) . After an initial intravenous injection of 250-1000 mg given slowly until cessation of seizures, continuous thiopental infusions (80-120 mg/h) for as long as 13 days have been used successfully in intubated and ventilated patients to control status epilepticus refractory to more conventional anticonvulsant drugs (170, 171) . The infusions were titrated to produce a burst suppression EEG pattern. Interestingly, the seizures did not recur after discontinuation of the infusion.
In one series of more than 900 patients with unspecified types of epilepsy, the frequency of epileptiform activity during anesthetic induction with methohexital was much less when compared with the previous sleep and awake EEGs of these epileptics (53). Methohexital has never been demonstrated to provoke either EEG or clinical seizure activity in patients with generalized convulsive disorders (11,159). Thus, although the epileptogenic effects of methohexital in patients with psychomotor epilepsy are well established, the ultrashort-acting barbiturates are predominantly potent anticonvulsant agents.
Etomidnte. The EEG patterns produced by etomidate are similar to those associated with thiopental (144,157,172). The main EEG difference between equihypnotic doses of etomidate (0.3 mg/kg) and thiopental(3.5 mg/kg) is a lack of beta activity during "light stages" of etomidate anesthesia (157) . Higher doses of etomidate produce burst suppression patterns analogous to the barbiturate compounds (157, 172) . Involuntary myoclonic movements are common during induction of anesthesia with etomidate, and occasionally resemble generalized convulsive seizures (145, 157, 173) . This myoclonus can persist into the recovery period (144-146). There have also been reports of generalized or focal convulsivelike movements occurring in ventilated patients receiving long-term etomidate infusions for sedation (174, 175) . However, EEG correlation was not performed and none of these patients had a previous or subsequent history of epilepsy. In one of these reports (175), the involuntary motor activity was suppressed with higher doses of etomidate.
Whether these convulsivelike movements associated with etomidate administration in nonepileptic patients represent seizure activity is unclear. Surface EEG studies performed in patients without a history of epilepsy treated with etomidate have not revealed spiking activity during these myoclonic movements (144, 157, 172) . In some of these patients, simultaneous electromyographic, plantar reflex, and soleus muscle M-wave/H-reflex recordings indicated that the etomidate-induced myoclonus was of spinal (nonepileptic) origin (144). Conversely, in one report of more than 30 nonepileptic patients undergoing open heart surgery, surface EEG monitoring demonstrated generalized epileptiform activity in approximately 20% of the cases after etomidate induction (176) (Table 5) . However, no myoclonic or convulsivelike movements were reported during these episodes of apparent EEG seizure activity.
Etomidate infusion produces a 2-to 12-fold increase in the amplitude of median (177) and posterior tibia1 (178) nerve somatosensory evoked potentials. The increased amplitude may represent an alteration of the balance of inhibitory and excitatory influences in the thalamocortical tracts (178, 179) . This suggests that etomidate could produce myoclonus either by blockade of inhibition or enhancement of excitability in these subcortical CNS tracts. Higher plasma levels of etomidate may prevent myoclonic movements by depressing both inhibitory and excitatory neuronal firing (175) .
It is also possible that the convulsivelike movements associated with etomidate could be due to subcortical seizure activity. Depth electrode investigations during etomidate administration have been performed in two patients, both suffering from temporal lobe epilepsy (180) . In these two cases, etomidate (0.2-0.3 mgikg, IV) induced an electrographic seizure originating from the known subcortical seizure foci. Because of concomitant nondepolarizing muscle relaxant administration, it is unknown whether or not myoclonic or convulsivelike movements would have been associated with this subcortical seizure activity.
Surface EEG studies in patients with a history of epilepsy have further documented the proconvulsant effects of etomidate (53,176,181) (Table 5) . In 39 epileptic patients, convulsionlike potentials were recorded within 30 s after anesthetic induction with etomidate and occurred more frequently than during sleep or awake EEG testing (53). Interestingly, no myoclonic or convulsivelike movements were reported during these episodes of etomidate-induced EEG seizure activity. In patients undergoing electrocorticography before temporal lobectomy for intractable complex partial seizure disorders, etomidate (0.2-0.3 mg/kg, IV) administered during or within 10 min of discontinuation of 50%-70% nitrous oxide (N,O) activated EEG epileptiform activity in more than 75% of the patients (176, 181) . The well-known EEG activating effects of N,O cannot be ruled out as an additive factor in these two reports. Furthermore, correlation between EEG and clinical seizure activity may have been prevented by concomitant nondepolarizing neuromuscular blockade. Interestingly, after etomidate induction, one of the epileptics studied exhibited grand ma1 convulsivelike movements before the institution of muscle relaxation and EEG monitoring (176) . Thus, it was unclear whether the clinical seizure observed in this case was due to corticalisubcortical epileptiform activity or exaggerated nonepileptic myoclonus.
Etomidate appears to possess anticonvulsant properties in both humans and animals. The drug increased the threshold for both narcotic-induced EEG seizures in dogs (8) and bicuculline-induced seizures in rats (182) . In amygdaloid kindled rats, etomidate suppressed seizure activity (183) . In humans, successful termination of EEG-documented status epilepticus has been demonstrated after etomidate administration (184, 185) (Table 6) .
Overall, etomidate has both pro-and anticonvulsant effects on EEG. In view of the finding that higher doses of the drug suppress low dose-induced involuntary motor activity, it appears that the dose and rate of etomidate administration probably determines which of its contrasting effects on the seizure threshold will occur in a particular clinical setting. Furthermore, additional studies of the EEG effects of progressively higher doses of etomidate (without concomitant muscle relaxation) are required to determine if etomidate-induced myoclonus is of epileptic or nonepileptic origin.
Benzodiazepines.
After diazepam (10-20 mg, IV) an increase in EEG amplitude can be seen in the beta band between 12 and 22 Hz. There is also a reduction in alpha activity and transient increases in amplitude in the deltaitheta band (186, 187) . The increased activity in the beta range is probably related to the major clinical effect of the benzodiazepines (e.g., sedation, amnesia). The percentage of beta activity appears to correlate with diazepam blood levels (187). Electroencephalographic or clinical seizure activity has not been reported in nonepileptic patients treated with benzodiazepines (Table 5 ).
The occurrence of status epilepticus has been reported with diazepam (188) (189) (190) . Although observed in one child with petit ma1 seizures (189), this paradoxical effect of diazepam usually occurs in patients with Lennox-Gastaut syndrome, a form of secondary generalized epilepsy (188, 190) . In these epileptics, benzodiazepines can induce brief episodes of EEG and clinical seizure activity (Table 5) .
In general, the benzodiazepines used in anesthetic practice possess potent anticonvulsant properties in both humans and animals. In humans, diazepam (191) and lorazepam (192, 193) have been widely used to terminate episodes of status epilepticus (Table 6) . Suppression of EEG seizure activity has been demonstrated after intravenous (191) , intramuscular (194) , and rectal (195) routes of administration. The absorption and efficacy of rectal diazepam appears to be analogous to or superior to that of the intramuscular route (195) . Midazolam (15 mg, IM) is as effective as diazepam (20 mg, IV) in abolishing interictal spikes (194) . Thus, although intravenous diazepam (or midazolam) is often regarded as the drug of choice in the emergency therapy of generalized seizure disorders, it appears that both intramuscular midazolam and rectal diazepam are acceptable alternative routes of administration in situations where it is not possible to establish intravenous access (194) . Not surprisingly, the duration of antiseizure activity after lorazepam (4-8 mg, IV) is longer than that achieved with intravenous diazepam (193) . Because of its high affinity for the benzodiazepine receptor (196) , repetitive doses of lorazepam are rarely required for continuing control of seizures. Overall, the benzodiazepines are effective in controlling status epilepticus occurring in more than 90% of patients with generalized seizure disorders. Also, they are effective in approximately 60% of cases of status epilepticus occurring in partial epilepsy (188) . Ketarrrine . In patients without a history of seizure disorder, cortical EEG recordings 1-2 min after ketamine (1-3 mg/kg, IV) are characterized by the initial appearance of fast beta activity at 3040 Hz, which is followed by moderate-voltage theta activity mixed with high-voltage delta waves recurring at 3-4-s intervals (140,186). Higher doses of ketamine (>2 mgikg, IV) produce a burst suppression EEG pattern. The 30-40-Hz activity is maximal frontally and tends to persist even when the theta and delta activity appears. The variety of EEG patterns produced by racemic ketamine have been attributed to differences between the drug's two optical isomers with regard to their anesthetic potency and EEG effects (Figure 4 ) (197, 198) . When the more potent S(+) isomer of ketamine is infused to produce a state of clinical anesthesia, a progressive decrease in EEG amplitude and frequency occurs, followed by intermittent highamplitude polymorphic delta activity. In contrast, larger doses of the less potent R(-) ketamine are unable to produce the same degree of EEG suppression. Electroencephalographic seizure activity has not been reported in nonepileptic patients during ketamine administration. However, the occurrence of myoclonic and seizurelike motor activity has been observed clinically in nonepileptic children and adults after intravenous (2 mg/kg) or intramuscular (10-12 mgikg) ketamine (199) (200) (201) (202) (203) (Table 5) . These movements were noted soon after induction (199) and later after additional incremental doses (202) (203) (204) . Unfortunately, simultaneous EEG recordings were not available. In four nonepileptic asthmatics receiving aminophylline, extensor-type seizures occurred within minutes after induction with ketamine (1-2 mg/kg, IV) (205). In mice, aminophylline appears to decrease the seizure threshold for ketamine (205) .
Although surface EEG recordings have not revealed seizure activity in nonepileptic patients treated with ketamine, it is conceivable that the convulsivelike movements observed in these nonepileptic patients could be due to subcortical seizure activity. After ketamine administration to normal cats, subcortical seizure activity has been recorded from chronically implanted depth electrodes. In these cats, ketamine produced intermittent hypersynchrony with spiking activity in the limbic system, which subsequently spread to subcortical nuclei and the neocortex (6,206,207) . This subcortical and cortical EEG seizure activity was associated with excitation, catalepsy, muscle twitching, and bizarre posturing. Furthermore, ketamine-induced subcortical activation was implicated as the cause of severe myoclonus in infants with myoclonic encephalopathy (Kinsborne syndrome) (208) . In view of these findings, it is possible that depth electrode EEG recordings in nonepileptic patients treated with ketamine would detect subcortical seizure activity with or without convulsivelike movements.
It is well-established that ketamine will activate epileptogenic foci in patients with known seizure disorders (16,63) ( Table 5 given ketamine (0.5-2.0 mg/kg, IV) did not report any cortical or clinical seizure activity with surface EEG monitoring. Conversely, intermittent paroxysmal epileptiform discharges were recorded on surface EEG in six of eight epileptic patients given ketamine (4-10 mg/kg, IM, followed by 1-20 mg/kg, IV, in divided doses) (63). Three of these patients manifested clinical convulsions with increases in seizure activity for up to 3 mo after ketamine administration. Subcortical withdrawal seizures have been reported for up to 5 days after discontinuation of ketamine in rats that were chronically exposed to the drug (210).
Ketamine appears to possess anticonvulsant properties in both humans and animals. In mice, ketamine prevented both electrical and pentylenetetrazolinduced seizures (21 l), whereas in rats, the drug terminated 3-mercaptopropionic acid-induced seizures (84). Corssen et al. (212) suggested that ketamine may have anticonvulsant properties because it effectively terminated tonic-clonic convulsions in two patients (Table 6) . Fisher (9) reported that ketamine (5-20 mg/kg, IM) produced cessation of grand ma1 seizure movements in two children with a history of multiple admissions for resistant status epilepticus. Furthermore, in three children with febrile convulsions unresponsive to conventional antiepileptic therapy, ketamine (14 mg/kg, IV, and 2.5 mg/kg, IM, on separate occasions) rapidly terminated clinical seizure . -.
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activity (10). In these children, ketamine's rapid onset of anticonvulsant action via the intramuscular route appeared to be a potential advantage over conventional intravenous anticonvulsants in treating status epilepticus. Unfortunately, in all of these reports, simultaneous EEG recordings were not available to further support these apparent anticonvulsant actions for ketamine. In addition, the available evidence indicates that ketamine possesses primarily potent cerebral stimulatory properties, especially in patients with seizure disorders in whom the drug activates subcortical seizure activity.
Propofol. Propofol is a newer intravenous anes-
thetic that can be used for both induction and maintenance of general anesthesia. In humans, propofol has been reported to produce excitatory activity (e.g., movements, myoclonus, muscle tremors, and hiccoughs) during induction of anesthesia (213). Although the incidence of the excitatory effects with propofol may be higher than with thiopental, the incidence appears to be less than with either methohexital or etomidate (213) . Whether these abnormal movements associated with propofol induction represent true seizure activity or merely nonepileptic myoclonia is unknown, as simultaneous EEG recordings have not been performed during these excitatory side effects. Unlike etomidate (174, 175) prolonged seizurelike excitatory movements during or after continuous infusion of propofol have not been observed. In patients without a history of seizure disorder, cortical EEG changes similar to those produced by 1990;70:43344 thiopental were demonstrated after propofol (2 mg/ kg, IV) (214, 215) . Neither epileptiform activity nor excitatory movements were reported (Table 5) . However, in three patients with a history of intractable temporal lobe epilepsy, Hodkinson et al. (216) described activation of epileptogenic foci after a bolus of propofol (2 mg/kg, IV). In each case, electrocorticography revealed frequent discharges of spikes, polyspikes, and spike and wave complexes 20-30 s after injection, continuing for up to 7 min. No patient exhibited excitatory motor effects and the EEG seizure activity ceased spontaneously.
Propofol appears to possess anticonvulsant properties clinically. However, there is no EEG documentation of this effect (Table 6 ). In a 21-yr-old woman with refractory status epilepticus caused by viral encephalitis, Wood et al. (217) reported that a single bolus of propofol(lO0 mg, IV) completely suppressed clinicaI seizure activity. After this, a continuous propofol infusion at 5-7 mg.kg-'.h-' continued to control her convulsions for 18 days. However, her seizures recurred whenever the infusion was discontinued. In two reports of patients with depressive disorders undergoing electroconvulsive therapy, the mean clinical seizure duration was significantly reduced after propofol (1.3-1.5 mg/kg, IV) compared with methohexital (1 mg/kg, IV) (218,219).
Local Anesthetics
Local anesthetics are well-known convulsants in patients with and without a history of seizure disorder (220, 221) (Table 5) . Clonic or tonic-clonic activity (64) has occurred after the administration of local anesthetics via the intravenous (220) (221) (222) , epidural (223, 224) , or peripheral nerve block (225) routes. Local anesthetic-induced convulsions have not been reported after subarachnoid administration (226) (227) (228) . High blood levels result from accidental intravascular injection, accumulation after repeated injections, and rapid systemic absorption from a highly vascular area (229) . Thus, seizures may be either immediate or delayed after local anesthetic administration.
Surface EEG recordings have not correlated well with the preconvulsive signs and symptoms of local anesthetic toxicity (64,229). Abnormal preseizure EEG activity was not found in humans after the production of preconvulsive signs and symptoms of toxicity by a variety of local anesthetic compounds (222, 230, 231) . The onset of cortical EEG seizure activity was simultaneous with tonic-clonic muscle activity. In contrast, depth electrode EEG recordings in monkeys treated with lidocaine have revealed a characteristic preconvulsive pattern of diffuse slowing and irregular appearance of large spikes leading directly into generalized seizure activity (232). However, similar to the findings for lidocaine in humans, mepivacaine, bupivacaine, and etidocaine do not consistently produce distinctive preconvulsive EEG changes in animals (229, 232, 233) .
Depth electrode EEG studies in both animals (232, 234, 235) and epileptic patients (220) have revealed a seizure focus in the limbic system (amygdala, hippocampus) after the administration of local anesthetics. Ablation of the amygdala has also been reported to prevent local anesthetic-induced seizures (64). In rats (236) , selective metabolic activation of the limbic system has been demonstrated during lidocaine-induced preseizure activity. These findings support a subcortical origin for local anestheticinduced seizures and suggest that the preconvulsive signs and symptoms of CNS toxicity in humans may be manifestations of psychomotor seizures (64,237).
Local anesthetics have also been demonstrated to possess anticonvulsant properties in both humans and animals. In general, the anticonvulsant activity of local anesthetic agents occurs at subtoxic blood levels (64,229). In cats in which seizures were produced by intracortical penicillin, a marked anticonvulsant effect was noted at lidocaine blood levels of <4.0 pg/mL (229). Blood levels >4.5 FgIrnL produced signs of cortical irritability, with seizure activity at levels B7.5 pg/mL. In humans, subtoxic doses of lidocaine (1-2 mg/kg, IV), followed by an infusion of 1-3 mgkg-'. h-', have been used to terminate status epilepticus (238) (239) (240) (241) (Table 6 ). In patients undergoing electroconvulsive therapy, investigators (242, 243) have found that prior administration of lidocaine (or procaine) prevents and/or reduces the duration of electrically induced seizures. In one of these studies (242) , after induction of anesthesia with thiopental (4 mg/kg, IV) progressively higher doses of lidocaine (1-11.2 mg/kg, IV) failed to produce seizure activity and were associated with progressively shorter durations of electrically induced convulsions. Furthermore, a lidocaine dose of 16.5 mg/kg, IV (which produced tonic-clonic convulsions in 50% of the patients) prevented electroshock-induced seizures. Unfortunately, none of these studies regarding the anticonvulsant effects of local anesthetics had the benefit of simultaneous EEG documentation.
Local anesthetics can possess both proconvulsant and anticonvulsant properties because of their membrane-stabilizing effects (244) . Although local anesthetics generally inhibit neuronal activity, it appears that excitatory pathways are more resistant than inhibitory pathways (64, 229, 242, 245) . Thus, at subtoxic doses, local anesthetics can act as anticonvulsants, sedatives, and analgesics (238, 246, 247) . At higher drug concentrations, resistant unopposed excitatory pathways can cause frank convulsions. Ultimately, with further increases in local anesthetic blood levels all pathways are inhibited, resulting in a generalized state of CNS depression (64,229,234).
Anesthetic Adjuvants
Muscle Relaxants
In humans, none of the muscle relaxants used in clinical anesthesia have been reported to cause either EEG or clinical seizure activity. However, at high concentrations, the primary metabolite of atracurium, laudanosine, can produce EEG and clinical seizure activity in animals (248-250). In anephric patients, short-term infusion of atracurium (3-5 pg.kg-'. min-') for renal transplantation produced maximum laudanosine blood levels of 0.3-1.0 pg/mL (251) . No intraoperative EEG changes or postoperative seizures were associated with these laudanosine concentrations. However, chronic infusion of atracurium (10-15 pg.kg-'.min-') to renally impaired patients in the intensive care unit was associated with laudanosine concentrations as high as 5.1 pg/mL (252) , blood levels shown to produce convulsions in rabbits (249). Significantly higher laudanosine concentrations (> 17 pg/mL) are required to induce seizures in dogs (248, 249) . Thus, although it appears that laudanosine levels during surgery are of little (if any) clinical concern, additional studies regarding the CNS effects of long-term atracurium infusions are needed, especially in patients with hepatic failure in whom the half-life of laudanosine is significantly prolonged (253) .
In animals, succinylcholine applied topically to the cerebral cortex produced intense EEG stimulation and seizure activity that was believed to be due to direct depolarization of neurons (254) . In both humans (255, 256) and animals (257, 258) anesthetized with halothane, intravenous succinylcholine produced EEG arousal that was associated with significant increases in cerebral blood flow and intracranial pressure. Prior administration of large doses of nondepolarizing muscle relaxants prevented both the EEG activation and intracranial pressure increases induced by intravenous succinylcholine, whereas smaller defasciculating doses had no effect (255, 258) . As little (if any) of the drug crosses the blood-brain barrier, the EEG arousal with increases in cerebral blood flowhntracranial pressure after intravenous succinylcholine is most likely related to succinylcholine-induced increases in afferent muscle spindle activity and to increases in Paco, generated by increased muscle carbon dioxide (CO,) production (258). In addition, the lack of EEG activation after succinylcholine injection in dogs with disrupted blood-brain barriers (259) further supports this hypothesis and indicates that intravenous succinylcholine does not possess proconvulsant properties.
Usubiaga et al. (260) reported that succinylcholine terminated procaine-and lidocaine-induced muscle seizure activity in humans, but did not affect the duration or pattern of EEG seizure activity. In monkeys, prior administration of gallamine increased the lidocaine EEG convulsive threshold (229) . In humans, none of the muscle relaxants used in clinical anesthesia have been reported to possess anticonvulsant properties.
Anticholinesterases
None of the cholinesterase inhibitors (CHEIs) used in clinical anesthesia have been reported to cause EEG or clinical seizure activity in humans. However, acetylcholine is an important component of seizure activity (261) . In contrast to the postictal state, brain acetylcholine levels and cerebrospinal fluid turnover increase during seizures. In animals monitored with depth electrodes (262) , CHEIs induced cortical and/or subcortical EEG seizure activity. These drugs also lower the threshold for strychnine-and pentylenetetrazol-induced convulsions (261) .
In humans, physostigmine appears to reverse CNS depression by increasing central cholinergic activity (263) . Its tertiary amine structure allows it to more freely cross the blood-brain barrier. Physostigmine can reverse scopolamine-induced sedation by reversing the acetylcholine depletion (264) . For drugs such as diazepam (265) , which cause sedation via noncholinergic pathways (e.g., GABAnergic mechanisms), physostigmine-induced central cholinergic activation may produce awakening because of a generalized "arousal" effect (263). This CNS "arousal" effect of physostigmine has been noted on EEG. In both dogs (266) and humans (263) anesthetized with halothane, clinical doses of physostigmine (0.3 mg/ kg, IV) shifted EEG activity from a low-frequency, high-amplitude pattern characteristic of anesthesia, to a higher frequency, lower amplitude awake-type pattern. Physostigmine also reverses the CNS excitation associated with the central anticholinergic syndrome produced by atropine and scopolamine (267, 268) . The underlying mechanism of these paradoxical effects for both physostigmine and anticholinergic agents is unclear.
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In humans, none of the CHEIs used in clinical anesthesia have been reported to possess anticonvulsant properties. In cats, physostigmine reversed a scopolamine-induced increase in enflurane EEG seizure activity (26). These unexpected effects probably involve noncholinergic pathways (269) . In clinically relevant doses, none of the CHEIs used in anesthetic practice would be expected to have significant effects on the seizure threshold in humans.
Anticholinergics
Based on their central cholinergic inhibitory actions, a sedative effect would be expected after clinical doses of the tertiary amine anticholinergic drugs. However, both atropine and scopolamine can produce unexpected CNS excitation and delirium (267, 268) . Although the precise mechanism of these excitatory effects is not known, it may involve central noncholinergic antagonist actions (270) and/or a paradoxical activation of nicotinic receptors in the brain (271). These CNS excitatory effects have not occurred with the quaternary amine compound, glycopyrrolate.
Because the central cholinergic system appears to be an important component in generating seizure activity, anticholinergic drugs with tertiary amine structures would be expected to possess anticonvulsant properties. When given alone, clinical doses of atropine (0.5 mg, IV), which can cause drowsiness, typically produce mild increases in deltakheta activity with slight decreases in beta activity. The dominant alpha band is variably affected (272) . Both atropine and scopolamine also depress the arousal response to photostimulation (273) . In humans, atropine (1.2 mg, IV) inhibits the increased EEG activity produced by di-isopropyl fluorophosphate, a CHEI (274). These investigators also observed that atropine reduced abnormal discharges of the EEG in patients with grand ma1 epilepsy. Spontaneous and hyperventilation-induced petit ma1 EEG paroxysmal discharges can also be blocked with atropine (275) . In animal studies, large doses of atropine and scopolamine have blocked seizures produced by exogenous acetylcholine and CHEIs (276) , and also significantly decreased enflurane-induced EEG spiking activity (51). In clinically relevant doses, neither atropine nor scopolamine would be expected to have a significant therapeutic effect on seizure activity in humans.
Summary
Perioperative seizures have numerous potential etiologies. In general, when seizures occur during surgery, their onset often coincides with the introduction of a specific anesthetic or analgesic drug. Conversely, postoperative seizures are more commonly due to nonanesthetic causes (277 Some anesthetics appear to possess both proconvulsant and anticonvulsant properties (Table 1) . One possible factor is an inherent pharmacodynamic variability in the responsiveness of inhibitory and excitatory target tissues in the CNS. This is well illustrated by the anticonvulsant and proconvulsant effects of progressively higher doses of local anesthetic drugs (64,229). This variability in neuronal responsiveness could also explain the conflicting findings for low versus high doses of fentanyl(l36,142) and etomidate (175, 178) . Furthermore, biological variation in the individual patient's responsiveness to certain anesthetic drugs could be an additional contributory factor.
Differing structure-activity relationships might also explain why some anesthetic agents possess both proconvulsant and anticonvulsant properties. Relatively minor modifications in a drug's structure can influence its affinity for a specific receptor site and its intrinsic pharmacologic activity. For example, when methohexital was first introduced, convulsions were commonly encountered in patients with and without a history of epilepsy (278) . Subsequent fractionation of the original compound into its two isomeric forms resulted in the identification of the isomer primarily responsible for this convulsive activity. In its present formulation (Brevital; Eli Lilly, Indianapolis, Ind.), the epileptogenic properties of methohexital are limited to patients with psychomotor epilepsy (11). However, compared with thiopental, excitatory effects are still more common with methohexital. The excitatory effects of methohexital are presumably due to its methylated structure (64). The inhaled anesthetic flurothyl (hexaflurodiethyl) ether and the intravenous anesthetic ketamine also illustrate how subtle changes in stereoisomerism can result in significant changes in structure-activity relationships (Figure 4) . Flurothyl, a fluorinated ether analogue, reliably produces convulsions in nonepileptic patients, whereas its structural isomer isoindoklon has not been associated with seizure activity (279) . Other examples of isomer or structural analogue relationships that produce differential effects on neuronal hyperexcitability include enflurane-isoflurane and meperidine-normeperidine.
In conclusion, the patient population (epileptic or nonepileptic), the method of documentation (EEG study or clinical observation), and the method of EEG analysis (cortical or depth electrodes) must be considered to properly analyze the proconvulsant and/or anticonvulsant properties of an anesthetic or analgesic drug. As more information regarding the site and mechanism of action of these drugs within the CNS becomes available with advances in in vivo imaging techniques (e.g., magnetic resonance imaging, positron emission tomography), our understanding of the conditions responsible for producing either proconvulsant or anticonvulsant properties should improve. Further advances in neurophysiology and neurochemistry will lead to improvements in the cIinical use of anesthetic and analgesic drugs during the perioperative period.
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